# Oncoverity We Seek a World Where Cancer Never Wins


## **Forward looking statement**

Information in this presentation and related comments of presenters contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are based on current expectations, forecasts, assumptions, and other information available to the company as of the date hereof. Forward-looking statements include, but are not limited to, implied and express statements about the company's strategy, future business plans, functionality, and capabilities; plans and timelines for clinical development of the company's therapies, including therapeutic potential and efficacy, clinical benefits, safety profiles, and plans to submit investigational new drug (IND) applications; the potential size of the commercial market for the company's treatment programs; the company's long-term financial targets, prospective financial results, return of capital plans, expectations about addressable markets and market share; and future business outlook, such as forward-looking statements about the company's expectations, beliefs, intentions, or strategies. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial conditions and operations, projected costs, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, forward-looking statements use terminology such as "anticipate", "believe", "could', "expect", "may", "estimate", "intend", "ongoing", "plan", "potential" "should", "will", and "would", although not all forward-looking statements contain these identifying words.


The Company's actual results, performance, or events may differ materially from these forward-looking statements made or implied due to a number of factors, risks, and uncertainties relating to the Company's business, including but not limited to: the timing and anticipated results of our current and future clinical trials, supply chain, strategy, and future operations; the risk that the results of prior preclinical and clinical studies may not be predictive of future results in connection with current or future clinical trials; the timing and outcome of any interactions with or approvals by regulatory authorities; obtaining, maintaining, and protecting our intellectual property; our relationships with existing and future investors and collaboration partners; the impacts of current macroeconomic and geopolitical events. The Company disclaims any warranties or representations (expressed or implied) related to the accuracy of forward-looking statements and you should not place undue reliance on our forward-looking statements. The company assumes no obligation and disclaims any obligation to update any forward-looking or other information included in this presentation, whether as a result of new information, future events or otherwise. This presentation contains trademarks, trade names, and trademarks of other companies, which are the property of their respective owners. This presentation is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation or require any registration or licensing within such jurisdiction.



## Acute Myeloid Leukemia (AML) requires a new, different approach for effective, sustained treatment outcomes



### Built to accelerate development through state-of-the-art capabilities



## Cusatuzumab, a first-in-class CD70 antibody

#### $\rightarrow$ Proven Activity in AML


- CD70 expressed on AML blasts, selectively on LSCs, not HSC
- CD70 expression is increased after HMA and venetoclax treatment

### ightarrow Significant Safety Advantage

• Strong safety profile: wide therapeutic window as CD70 is only transiently expressed on healthy cells (T, B, DC)

#### ightarrow Dual Mechanism of Action

- 1 Kills blasts and LSCs selectively through NK-ADCC
  3 Blocks CD70 proliferation and survival signal;
- Blocks CD70 proliferation and survival sig inducing differentiation of LSC's






Abbreviations: LSC-Leukemic Stem Cells; HSC-Hematopoietic Stem Cells; HMA-Hypomethylating Agents; NK-Natural Killer Cells; ADC C-Antibody Dependent Cellular Cytotoxicity. References: Bertrand P et al, Genes, Chromosomes and Cancer 2013; Riether C et al, J Exp Med. 2017; Jacobs J et al Pharmacol Ther 2015; Bowman MR et al, J Immunol. Nolte MA et al, Immunol Rev. 2009; Riether C et al. Nat Med. 2020; Silence, K, et al. Landes Biosciences. 2013.

## cusatuzumab has potential to treat a broad range of tumors with particularly strong rationale in AML

#### CD70 is broadly implicated in various cancers 1, 2...


### ...with particularly strong biologic rationale in AML 3, 4

#### **Expression on malignant cells**



- CD70: interesting target for a broad range of malignancies
- Co-expression of CD70 & CD27 in lymphoma/ leukemia
- CD70 as a potential target for immunotherapy in solid tumors

#### Expressed on 96-100% of AML blasts, selectively on LSCs, not HSCs



- Cusatuzumab targets across all AML risk categories 3, 4
- Higher CD70 expression in monocytic blasts makes it a target for difficult to treat monocytic AML cells thought to be responsible for early relapse after SoC treatment. (figure in slide 45)
- Besides scientific rationale, safety profile allows combination with other key assets in AML / MDS paradigm



## Several cusatuzumab trials support future AML marketing approval

	$\rightarrow$		
2016	2017 Complete	2019 On-Going	<b>2020</b> On-Going
<b>Pre-Clinical Studies</b>	Phase 1/2   ARGX-1601	Phase 2   CULMINATE	Phase 1b ELEVATE
Showed ability to eliminate leukemic stem cells & increase survival in animal models Data showed that cusa could overcome ven/aza resistance	<ul> <li>N=38 Open Label Study</li> <li>Key Takeaway: No dose limiting toxicities</li> <li>Single agent activity demonstrated &amp; showed that cusa + aza leads to strong responses in elderly AML patients</li> </ul>	<ul> <li>N=103</li> <li>Randomized cusa (10mg/kg vs. 20mg/kg)</li> <li><i>Key Takeaway: 20 mg/kg cohort</i> (n=52) with strong safety &amp; tolerability demonstrated</li> <li>Showed dose dependent and durable response in 20mg/kg cohort of cusa + aza in frail patients</li> </ul>	<ul> <li>N=44</li> <li>Open label, multi-center</li> <li><i>Key Takeaway: Deep responses</i> <i>even among challenging</i> <i>patient population</i></li> <li>Includes new SOC ven/aza + cusa on-going trial</li> <li>Adds efficacy to ven/aza</li> </ul>


Note: Standard of Care (SOC) in unfit AML evolved from azacitidine to ven/aza



# CULMINATE dose-optimization study demonstrated clinical activity, safety and tolerability

### Totality of clinical evidence supports 20 mg/kg as optimal cusa dose

CULMINATE Randomized Phase 2 (ITT)					
	cusa 10 mg/kg+Aza N=51	cusa 20 mg/kg+Aza N=52			
ORR (CR + CRh + CRi), n (%)	15 (29)	21 (40)			
CR, n (%)	6 (12)	14 (27)			
Median DoR, months (95% CI)	5.6 (0.7, NE)	13.6 (6.3, NE)			
Median OS, months (95% CI)	5.1 (3.3, 11.3)	9.9 (5.5, 16.2)			
Red blood cell/platelet transfusion independence, %	29/39	42/52			



#### Pabst et al, Lancet Heme 2023



AE, adverse event; AMI, acute myeloid leukemia; aza, azacitidine; cusa, cusatuzumab; DoR, duration of response; CR, Complete remission; CRh, complete remission with partial hematological recovery; CRi, complete remission with incomplete hematological recovery; ITT, intention-to-treat; NE, not estimable; ORR, overall response rate; OS, overall survival.

## **ELEVATE combined cusa with standard of care**

### Response rates suggest an additive effect of cusa to standard of care

### ELEVATE Phase 1b ven/aza/cusa in newly diagnosed elderly unfit

	All Patients N=44	Response Evaluable N=42*	
ORR (CR + CRh + CRi), n (%)	34 (77.3)	34 (81.0)	
Best response, n (%)	-		
CR	21 (47.7)	21 (50)	
CRi	13 (29.5)	13 (31)	
CRh	9 (20.5)	9 (21.4)	
MRD negativity after initial response	18 (52.9)	18 (52.9)	
Red blood cell/platelet transfusion independence, %	66/80	69/84	

\* Two patients did not have post-baseline disease evaluation due to death

#### **Key Notes/Insights**

- ORR of 81%, CR of 50% and MRD negativity of 53% compares favorably to historical controls
  - VIALE-A: CR 37%, CR/CRi 66%, 23% MRD negativity
- No obvious significant toxicities noted due to the addition of cusatuzumab
  - Mild IRRs (1 Grade 4)



Note: Data cut-off 9 November 2021, with median follow -up of 43.1 weeks. Patients received cusatuzumab 20 mg/kg intravenously on days 3 and 17 with standard dose of azacitidine and venetoclax in 28-day cycles. AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematological recovery; CRi, complete remission with incomplete hematological recovery; IRR, infusion-related reaction; MRD, measurable residual disease; ORR, overall response rate. 1. Roboz GJ, et al. Blood. 2021;138(suppl 1):369-372. 2. OncoVerity, data on file. 3. DiNardo CD, et al. N Engl J Med. 2020;383:617-629.

## Safety: cusa tolerability established in >300 patients



Well tolerated with no MTD identified across 6 studies involving 316 patients<sup>1-7</sup>



Combined with ven/aza had a safety profile consistent with that previously reported for ven/aza, with the exception of infusion-related reactions (IRRs)<sup>1</sup>



IRRs are typically low grade and manageable, and can be reduced with premedication<sup>1-3,a</sup>




1. Roboz GJ, etal. Blood. 2021;138(suppl 1):369-372. 2. Pabst T, et al. Haematologica. 2023:108:1793-1802. 3. Pabst T, et al. Lancet Haematol. 2023;10:902-912. 4. Riether C, et al. Nature Medicine. 2020;26:1459-1467. 5. De Meulenaere A, et al. Clin Transl.Sci. 2021;14:2300-2313. 6. Leupin N, et al. Cancer. 2022;128:1004-1014. 7. Aftimos P, et al. Clin Cancer Res. 2017;23:6411-6420. °Premedication consists of acetaminophen, diphenhydramine, and corticosteroids. MTD, maximum tolerated dose.

# Compelling comparative data support development of cusa in triplet combination

More favorable outcomes in AML patients treated with cusa/ven/aza in ELEVATE

(n=33) vs retrospective single center control cohort treated with ven/aza (n=211)

Kaplan-Meier analysis of overall survival (OS)





Patients receiving ven/aza were ~1.3x more likely to die than those receiving cusa/ven/aza (aHR: 0.78; 95% CI: 0.41-0.88)



Longer OS benefit with triplet over time (log-rank [proportional)] based p-value: 0.0859



Diverging survival noted with a stable plateau for triplet starting at ~700 days post-treatment




No substantial differences in toxicity



Note: Patients receiving potentially curative hematopoietic stem cell transplant were excluded from the ELEVATE and retrospective control cohort analysis. AML, acute myeloid leukemia; aza, azacitidine; CR, complete remission; CRi, complete remission with incomplete hematological recovery; cusa, cusatuzumab; OS, overall survival; ven, venetoclax. OncoVerity, data on file.

# OV- AML 1231: Randomized phase II trial of ven/aza/cusa vs ven/aza in elderly/unfit AML



## Potential additional indications beyond AML

	<ul> <li>cusatuzumab beyond AML</li> </ul>						
	Indication (new pts 2023 US)	CD70 literature	Preclinical or in-vivo CD70	cusatuzumab clinical data			
AML	AML (20k)						
Heme Malignancies	TCL (inc CTCL) (8k)						
	ALL (7k)						
	CLL (19k)				<ul> <li>Pipeline Expansion</li> <li>Collaboration with argenx on novel targets</li> <li>Partnerships to propel pipeline</li> </ul>		
	CML (9k)						
	DLBCL (17K)						
	MCL (2K)						
	ММ (36К)						
	Waldenstrom Macroglobulinemia (1.5k)				a differences to proper pipetine		
	LR-MDS						
Solid tumor	Lung (235.8k)			*			
	Head and neck cancer (60k)			*			
	Ovarian cancer (21.4k)			*			
	Pancreatic (60.4k)			*			
	Renal cancer (76k)			*			



## Summary: Transforming hope to reality for cancer patients

## Pioneer in applying computational tools to clinical and biological data advance therapies



Phase 2 clinical stage oncology company



**Transforming care in ongoing AML trials** Cusatuzumab: dual mode of action, robust and durable response, safety established in >300 patients



**Revolutionizing Drug Development** Applying computational tools to accelerate and de-risk oncology drug development



Addressing significant AML unmet need in first line patients



\$72M in Series A: Strong existing investor support



Market opportunity in AML is expected to grow to \$5B by 2032 with 11% CAGR

